Search results
Where Will Editas Medicine Be in 1 Year?
Motley Fool· 1 year agoGene-editing specialist Editas Medicine (NASDAQ: EDIT) fits the bill, which is why the company's shares have plunged this year. Could this be what's in...
Is Editas Medicine Stock a Buy Now?
Motley Fool· 11 months agoInvestors tend to move away from somewhat speculative stocks when the economic going gets rough. Editas Medicine's most advanced candidate is EDIT-301,...
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest...
Simply Wall St. via Yahoo Finance· 4 days agoEditas Medicine, Inc. (NASDAQ:EDIT) just released its latest quarterly report and things are not...
Could Editas Medicine Become the Next CRISPR Therapeutics?
Motley Fool via Yahoo Finance· 4 months agoEditas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few...
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 week agoEditas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript May 8, 2024 Editas Medicine,...
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 69%
Simply Wall St. via Yahoo Finance· 6 months agoKey Insights Institutions' substantial holdings in Editas Medicine implies that they have...
Editas Medicine, Inc. (NASDAQ:EDIT) is largely controlled by institutional shareholders who own 74%...
Simply Wall St. via Yahoo Finance· 1 year agoEvery investor in Editas Medicine, Inc. (NASDAQ:EDIT) should be aware of the most powerful...
The past three years for Editas Medicine (NASDAQ:EDIT) investors has not been profitable
Simply Wall St. via Yahoo Finance· 10 months agoEditas Medicine, Inc. (NASDAQ:EDIT) shareholders should be happy to see the share price up 10% in...
Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 23%
Simply Wall St. via Yahoo Finance· 5 months agoEditas Medicine, Inc. (NASDAQ:EDIT) shareholders will have a reason to smile today, with the...
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
Motley Fool via Yahoo Finance· 4 months agoInvesting in cutting-edge companies is a bit riskier than investing in tried-and-tested players, but...